These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 26585427)

  • 1. Ertapenem in the treatment of multidrug-resistant tuberculosis: first clinical experience.
    Tiberi S; D'Ambrosio L; De Lorenzo S; Viggiani P; Centis R; Sotgiu G; Alffenaar JW; Migliori GB
    Eur Respir J; 2016 Jan; 47(1):333-6. PubMed ID: 26585427
    [No Abstract]   [Full Text] [Related]  

  • 2. Pharmacokinetics of ertapenem in patients with multidrug-resistant tuberculosis.
    van Rijn SP; van Altena R; Akkerman OW; van Soolingen D; van der Laan T; de Lange WC; Kosterink JG; van der Werf TS; Alffenaar JW
    Eur Respir J; 2016 Apr; 47(4):1229-34. PubMed ID: 26743484
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Carbapenems to Treat Multidrug and Extensively Drug-Resistant Tuberculosis: A Systematic Review.
    Sotgiu G; D'Ambrosio L; Centis R; Tiberi S; Esposito S; Dore S; Spanevello A; Migliori GB
    Int J Mol Sci; 2016 Mar; 17(3):373. PubMed ID: 26985890
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment outcomes in extensively resistant tuberculosis.
    Chan ED; Strand MJ; Iseman MD
    N Engl J Med; 2008 Aug; 359(6):657-9. PubMed ID: 18687654
    [No Abstract]   [Full Text] [Related]  

  • 5. Final treatment outcomes of multidrug- and extensively drug-resistant tuberculosis patients in Latvia receiving delamanid-containing regimens.
    Kuksa L; Barkane L; Hittel N; Gupta R
    Eur Respir J; 2017 Nov; 50(5):. PubMed ID: 29122917
    [No Abstract]   [Full Text] [Related]  

  • 6. Phenotypic and genotypic analysis of multidrug-resistant tuberculosis in Ethiopia.
    Agonafir M; Lemma E; Wolde-Meskel D; Goshu S; Santhanam A; Girmachew F; Demissie D; Getahun M; Gebeyehu M; van Soolingen D
    Int J Tuberc Lung Dis; 2010 Oct; 14(10):1259-65. PubMed ID: 20843416
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recruitment challenges for clinical trials with novel regimens for drug-resistant tuberculosis.
    Siwendu S; Mitchell M; Diacon AH; von Groote-Bidlingmaier F
    Eur Respir J; 2016 Feb; 47(2):670-2. PubMed ID: 26647435
    [No Abstract]   [Full Text] [Related]  

  • 8. Management of drug-resistant TB with individualised DST--the way forward?
    Singhal T; Gupta N
    J Assoc Physicians India; 2014 Jul; 62(7):561-3. PubMed ID: 25672025
    [No Abstract]   [Full Text] [Related]  

  • 9. Multidrug-resistant tuberculosis (TB) resistant to fluoroquinolones and streptomycin but susceptible to second-line injection therapy has a better prognosis than extensively drug-resistant TB.
    Chan ED; Strand MJ; Iseman MD
    Clin Infect Dis; 2009 Mar; 48(5):e50-2. PubMed ID: 19191632
    [TBL] [Abstract][Full Text] [Related]  

  • 10. β-Lactams against Tuberculosis--New Trick for an Old Dog?
    Diacon AH; van der Merwe L; Barnard M; von Groote-Bidlingmaier F; Lange C; García-Basteiro AL; Sevene E; Ballell L; Barros-Aguirre D
    N Engl J Med; 2016 Jul; 375(4):393-4. PubMed ID: 27433841
    [No Abstract]   [Full Text] [Related]  

  • 11. Bedaquiline in MDR/XDR-TB cases: first experience on compassionate use.
    Tiberi S; De Lorenzo S; Centis R; Viggiani P; D'Ambrosio L; Migliori GB
    Eur Respir J; 2014 Jan; 43(1):289-92. PubMed ID: 23988772
    [No Abstract]   [Full Text] [Related]  

  • 12. Unsexy tuberculosis.
    Reichman LB
    Lancet; 2009 Jan; 373(9657):28. PubMed ID: 19121719
    [No Abstract]   [Full Text] [Related]  

  • 13. Extensively drug-resistant tuberculosis in South Africa.
    Bhuniya S
    Lancet; 2010 Aug; 376(9742):681; author reply 681-2. PubMed ID: 20801394
    [No Abstract]   [Full Text] [Related]  

  • 14. Treatment of multidrug-resistant and extensively drug-resistant tuberculosis in adolescent patients.
    Rodrigues M; Brito M; Villar M; Correia P
    Pediatr Infect Dis J; 2014 Jun; 33(6):657-9. PubMed ID: 24642519
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of extensively drug-resistant tuberculosis in Tomsk, Russia: a retrospective cohort study.
    Keshavjee S; Gelmanova IY; Farmer PE; Mishustin SP; Strelis AK; Andreev YG; Pasechnikov AD; Atwood S; Mukherjee JS; Rich ML; Furin JJ; Nardell EA; Kim JY; Shin SS
    Lancet; 2008 Oct; 372(9647):1403-9. PubMed ID: 18723218
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association of drug susceptibility testing results for first- and second-line drugs with treatment outcomes in patients with multidrug-resistant and extensively drug-resistant tuberculosis.
    Hong-min W; Xiao-Hong Z
    Clin Infect Dis; 2015 Apr; 60(8):1285-6. PubMed ID: 25552551
    [No Abstract]   [Full Text] [Related]  

  • 17. Comment on: Daily 300 mg dose of linezolid for the treatment of intractable multidrug-resistant and extensively drug-resistant tuberculosis.
    Yew WW; Chang KC; Chau CH
    J Antimicrob Chemother; 2009 Nov; 64(5):1119; author reply 1119-20. PubMed ID: 19666903
    [No Abstract]   [Full Text] [Related]  

  • 18. Daily 300 mg dose of linezolid for the treatment of intractable multidrug-resistant and extensively drug-resistant tuberculosis--authors' response.
    Koh WJ; Shim TS
    J Antimicrob Chemother; 2009 Nov; 64(5):1119-20. PubMed ID: 19744986
    [No Abstract]   [Full Text] [Related]  

  • 19. Early access to bedaquiline for extensively drug-resistant (XDR) and pre-XDR tuberculosis.
    Vasilyeva I; Mariandyshev A; Kazennyy B; Davidavičienė E; Lounis N; Keim S;
    Eur Respir J; 2019 Jul; 54(1):. PubMed ID: 31097518
    [No Abstract]   [Full Text] [Related]  

  • 20. Linezolid to treat MDR-/XDR-tuberculosis: available evidence and future scenarios.
    Sotgiu G; Pontali E; Migliori GB
    Eur Respir J; 2015 Jan; 45(1):25-9. PubMed ID: 25552734
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.